Supporting the role of the United States in helping save the lives of children and protecting the health of people in low-income countries with vaccines and immunization through Gavi, the Vaccine Alliance ("Gavi").

This resolution expresses the House of Representatives' strong support for the United States' ongoing role in Gavi, the Vaccine Alliance, as a crucial mechanism for delivering vaccines and immunization to low-income countries. Gavi, a public-private partnership established in 2000 with U.S. involvement, has significantly expanded access to vaccines, immunizing over 1.1 billion children and averting an estimated 18.8 million deaths in the world's most impoverished nations. This initiative has been instrumental in reducing childhood deaths from vaccine-preventable diseases by 70 percent since its inception, demonstrating its profound impact on global health. Gavi's model emphasizes country ownership and sustainability, requiring recipient nations to contribute to vaccine costs and invest in their immunization programs. It has also transformed the vaccine market by pooling demand and securing predictable financing, making vaccines more affordable and reliable. Beyond routine immunizations, Gavi supports critical efforts like polio eradication, stockpiling vaccines for outbreaks, and expanding access to new malaria vaccines, which have the potential to save tens of thousands of lives annually. The alliance also strengthens health systems, as demonstrated by its role in COVAX and its response to COVID-19, delivering nearly 2 billion doses and averting millions of deaths. The resolution affirms that U.S. government support for Gavi is a cost-effective and efficient means to reduce mortality, contributing to the U.S. goal of ending preventable child and maternal deaths and enhancing U.S. health security. It encourages the continued use of Department of State and CDC resources to bolster local public health capacity for vaccine delivery. Furthermore, the resolution calls for multiyear pledges and increased U.S. investment in Gavi for its 2026-2030 strategic period, ensuring predictability and stability in the vaccine market and fostering global health security.